Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

QIAGEN Shareholders Approve Return of Approximately $250 million in Cash to Shareholders via Synthetic Share Repurchase

QIAGEN
Posted on: 26 Oct 16

VENLO, the Netherlands, October 26, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved a proposal to return approximately $250 million in cash to shareholders through a synthetic share repurchase plan that combines a direct capital repayment with a reverse stock split. The capital repayment forms part of a commitment announced in July 2016 to return $300 million to shareholders by the end of 2017.

Following the announcement of the synthetic share repurchase plan in August 2016, shareholders at an Extraordinary General Meeting of Shareholders (EGM) today approved all three proposals to amend the Company's Articles of Association to allow for an adjustment in QIAGEN's share capital in order to complete the related capital repayment. Similar approaches have previously been used by other large, multinational Dutch companies as an efficient way to provide returns to all shareholders, and to do so in a faster and more efficient way than through a traditional open-market share repurchase program.

The transactions are expected to be completed in early January 2017 following the expiration of a two-month creditor objection period, which is required by Dutch law and begins after filing of the EGM resolution with the Dutch Trade Register and publication in a Dutch daily newspaper.

Click here for full press release

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={5889E407-DE47-4BF5-9B47-2DB06BAFBBAF}&lang=en

Contacts:

QIAGEN

Investor Relations
John Gilardi
ir@QIAGEN.com
+49-2103-29-11711

Public Relations
Dr. Thomas Theuringer
pr@QIAGEN.com
+49-2103-29-11826

For more information:
www.prnewswire.com/news-releases/qiagen-shareholders-approve-return-of-approximately-250-million-in-cash-to-shareholders-via-synthetic-share-repurchase-598647361.html

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 26/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.